Exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. To date, three medicines discovered at Exelixis have received regulatory approval to treat different types of cancer. We are steadfast in our commitment to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients in need of new treatment options.


Mar 29 2017 4:00pm EDT
21.13 -0.15

Investor Briefing at ESMO 2016 Congress

Exelixis management and invited guests discussed new data for cabozantinib being presented at ESMO, including the results of the CABOSUN phase 2 randomized trial. We apologize for any connectivity issues you experienced with the live stream, but the replay and related materials are now available.

See the video replay
Hear the audio-only replay
Download slides